# LITERATURE CITED

Andrew, R.L. 1996. **Molecular Modelling.** Addison Wesley Longman Limited, Harlow.

Bruera, E. 1992. Current pharmacological management of anorexia in cancer patients. **Oncology**. 6: 125-130.

Consoli, A., N. Nurjhan, F. Capani and J. Gerich. 1989. Predominant role of gluconeogenesis in increased hepatic glucose-production in Niddm. **Diabetes.** 38: 550-557.

Ernst, E. and B.R. Cassileth. 1999. How useful are unconventional cancer treatment? **Eur. J. Cancer.** 35: 1608-1613.

Fortney, S.R., D.A. Clark and E. Stein. 1967. Inhibition of gluconeogenesis by hydrazine administration in rats. **J. Pharmacol Exp Ther.** 156: 277-284.

Frisch, M.J., G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, J.A. Montgomery, T. Vreven, K.N. Kudin, J.C. Burant, J.M. Millam, S.S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G.A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J.E. Knox, H.P. Hratchian, J.B. Cross, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, P.Y. Ayala, K. Morokuma, G.A. Voth, P. Salvador, J.J. Dannenberg, V.G. Zakrzewski, S. Dapprich, A.D. Daniels, M.C. Strain, O. Farkas, D.K. Malick, A.D. Rabuck, K. Raghavachari, J.B. Foresman, J.V. Ortiz, Q. Cui, A.G. Baboul, S. Clifford, J. Cioslowski, B.B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R.L. Martin, D.J. Fox, T. Keith, M.A. Al-Laham, C.Y. Peng, A. Nanayakkara, M. Challacombe, P.M.W. Gill, B. Johnson, W. Chen, M.W. Wong, C. Gonzalez and J.A. Pople. 2003. **Gaussian 03**, revision B.05; Gaussian, Inc., Pittsburgh.

Gershanovich, M.L. and V.A. Filov. 1979. Hydrazine sulfate in late stage cancer: completion of initial trails in 225 evaluable patients**. Proc. Am. Assoc. Cancer Res.** 20: 240.

Gold, J. 1966. Metabolic profiles in human solid tumors: I. A new technic for the utilization of human solid tumors in cancer research and its application to the anaerobic glycolysis of isologous benign and malignant colon tissues. **Cancer Res.** 26: 695-705.

_____. 1974. Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy. **Oncology.** 29: 74-89.

_____. 1975. Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. **Oncology.** 35: 1-10.

_____. 1981. Anabolic profiles in late-stage cancer patients responsive to hydrazine sulfate. **Nutr Cancer.** 3: 13-19.

Hughes, T.K., P. Cadet and C.S. Larned. 1989. Modulation of tumor necrosis factor activities by a protection antichachexia compound, hydrazine sulfate. Int **J. Immunopharmacol.** 11: 501-507.

Jia, F., D.C. Morrison and R. Silverstein. 1994. Hydrazine sulfate selectively modulates TNF response to endotoxin in mouse macrophases. **Circ Shock.** 42: 111-114.

Kaegi, E. 1998. Unconventional therapies for cancer. **CMAJ.** 158: 1327-1330.

Kuno, M., R. Honskrengkai and S. Hannongbua. 2006. ONIOM-BSSE scheme for H---$\pi$ system and applications on HIV-1 reverse transcriptase. **Chem. Phys. Lett**. 424: 172-177.

Lee, M.H., C.A. Hebda and T. Nowak. 1981. The role of cations in avian liver phosphoenolpyruvate carboxykinase catalysis. **J. Biol. Chem.** 256: 12793-12801.

Li, W., C. Qi, X. Wu, H. Rong and L. Gong. 2008. Theoretical investigation of interactions between glycine cation based ionic liquids and water molecules. **J. Mol. Struct.: THEOCHEM**. **xxx**, xxx-xxx.

.

Macbeth, R. and J.G. Bekisi. 1962. Oxygen consumption and anaerobic glycolysis of human malignant and noral tissue. **Cancer Res.** 22: 244-248.

Magnusson, I., D.L. Rothman, L.D. Katz, R.G. Shulmana and G.I. Shulman. 1992. Increased rate of gluconeogenesis in type Ii Diabetes-Mellitus: A C-13 nuclear-magnetic-resonance study. **J. Clin. Invest.** 90: 1323-1327.

Nunrium, P., M. Kuno, S. Saen-oon and S. Hannongbua. 2005. Particular interaction between efavirenz and the HIV-1 reverse transcriptase binding site as explained by the ONIOM2 method. **Chem. Phys. Lett.** 405: 198-202.

Ochoa, M.Jr., R.E. Wittes and I.H. Krakoff. 1975. Trail of hydrazine sulfate (NSC-150014) in patients with cancer. **Cancer Chemother Rep.** 58: 1151-1154.

Ray, P.D., R.L. Hanson and H.A. Lardy. 1970. Inhibition by hydrazine of gluconeogenesis in the rat. **J. Biol. Chem**. 245: 690-696.

Saen-oon, S., M. Kuno and S. Hannongbua. 2005. Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl *TIBO* complex structures: quantum chemical calculations based on the ONIOM method. **Prot.: Struct. Func. Bioinf.** 61: 859-869.

Seits, J.F., M.L. Gershanovich and V.A. Filov. 1975. Experimental and clinical data on the antitumor action of hydrazine sulfate. **Vopr. Onkol.** 21: 45-52.

Silverstein, R., P. Bhatia and D.J. Svoboda. 1989. Effect of hydrazine sulfate on glucose-regulating enzymes in the normal and cancerous rat. **J. Immunopharmacol.** 17: 37-43.

Tayek, J.A., D. Heber and R.T. Chlebowski. 1987. Effect of hydrazine sulfate on whole-body protein breakdown measured by $^{14}$C-Lysine metabolism in lung cancer patients**. Lencet.** 330: 241-244.

Thomas, M.K., S.W. Peter and C.T. Inis. 1996. Reaction of hydrazinium azide with sulfuric acid : The X-Ray structure of $[N_2H_6][SO_4]$. **Polyhedron.** 15: 2579-2582.

Toth, B. 1996. A review of the antineoplastic action of certain hydrazines and hydrazine-containing nutral products. **In Vivo.** 10: 65-96..

Warburg, O. 1956. On the origin of cancer cells**. Science.** 123: 309-314.

Wierzejewska, M. and D.J. Sompolski. 2008. *Ab initio* MP2 and FTIR matrix isolation studies on *tert*-butanethiol complexes with water. **J. Mol. Struct.** 872: 166-175.

Wu, J., J. Zhang, Z. Wang and W. Cao. 2007. Theoretical study on intermolecular interactions in $BrF/H_nX$ adducts. **J. Chem. Phys.** 338: 69-74.